C4 Therapeutics Announces Clinical Trial Collaboration with Pfizer to Combine Cemsidomide and Elranatamab for Multiple Myeloma Treatment
Reuters
Oct 01, 2025
C4 <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces Clinical Trial Collaboration with Pfizer to Combine Cemsidomide and Elranatamab for Multiple Myeloma Treatment
C4 Therapeutics Inc. has announced a clinical trial collaboration and supply agreement with Pfizer Inc. to evaluate a new treatment combination for relapsed or refractory multiple myeloma. Under the agreement, Pfizer will supply its BCMAxCD3 bispecific antibody, elranatamab (ELREXFIO®), for use in an upcoming Phase 1b clinical trial sponsored by C4 Therapeutics. The trial will assess the safety and tolerability of combining cemsidomide, an IKZF1/3 degrader, and dexamethasone with elranatamab as a second-line or later therapy. The collaboration aims to identify an optimal dose for the combination and explore its potential to improve patient outcomes in multiple myeloma. The trial is expected to begin in the second quarter of 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. C4 Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9538001-en) on October 01, 2025, and is solely responsible for the information contained therein.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.